DOCSLIB.ORG

Jazz Pharmaceuticals Plc Proxy Statement 2017 Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Proxy Statement Proxy 2017 Annual Report Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc Proxy Statement — 2017 Annual Report June 15, 2018 Dear Shareholders, Over the past six years, Jazz Pharmaceuticals has evolved into an integrated global biopharmaceutical company, with deep therapeutic expertise in serious sleep disorders and hematology/oncology-related diseases. During this time, we have deployed approximately $4 billion in capital to meaningfully diversify our business, received multiple global regulatory approvals and launched two new hematology/oncology products, while making significant advancements in multiple R&D programs. Our commitment to investing in new, innovative therapeutic options for patients while driving long-term, Meet John sustainable growth for our shareholders has remained unwavering and was demonstrated by our pivotal Our cover highlights John. After working achievements in 2017. in the steel industry for 45 years, John retired in 2009 and, with his wife Cherie, In 2017, we received marketing authorization for and began traveling the world visiting family successfully launched Vyxeos® (daunorubicin and and friends and seeking new adventures. cytarabine) liposome for injection in the U.S., the first In 2013, John noticed changes in his new chemotherapy advance in more than 40 years for health. He was fatigued, bruised easily and adults with certain types of high-risk AML. We also was not his usual energetic self. Shortly announced positive results from our three Phase 3 studies thereafter, John was diagnosed with of solriamfetol for the treatment of excessive sleepiness acute myeloid leukemia, or AML, a rapidly (ES) in narcolepsy and obstructive sleep apnea (OSA) progressing and life-threatening blood and from our Phase 2/3 study of Xyrem® (sodium cancer. Given his age and limited treatment oxybate) oral solution in a pediatric narcolepsy population. options, John’s doctor advised him of a clinical We accomplished significant regulatory milestones in trial for Vyxeos (known then as CPX-351) multiple late-stage sleep and hematology/oncology clinical which, at that time, was an investigational programs, including: chemotherapy drug for patients with certain types of poor-prognosis AML. John decided to • Submission of a new drug application (NDA) for pursue this option and was enrolled in the clinical solriamfetol in the U.S. trial. John received Vyxeos and later went on to • Submission of a marketing authorization application receive a bone marrow transplant. Today, John and under an accelerated pathway for Vyxeos in the EU. Cherie are back to living each day to the fullest. • Receipt of marketing authorization for Defitelio® (defibrotide sodium) in Canada. In August 2017, the U.S. Food and Drug • Initiation of a Phase 3 study of JZP-258, our product ® Administration approved Vyxeos (daunorubicin candidate with 90% less sodium content compared and cytarabine) liposome for injection for to Xyrem, for the treatment of excessive daytime the treatment of adults with newly-diagnosed sleepiness and cataplexy in narcolepsy. therapy-related AML or AML with myelodysplasia- • Initiation of a Phase 2 study of solriamfetol for the related changes. Vyxeos represents the first new treatment of excessive sleepiness in Parkinson’s disease. chemotherapy advance in more than 40 years for adults with these two types of AML. Additionally, we diligently evaluated, and continue to The patient story shared in this communication depicts an individual evaluate, many corporate development opportunities to patient’s response to our medicine and is not representative of all expand our business and pipeline. In 2017, we were patient responses. pleased to announce collaborations with ImmunoGen, (TA-TMA). With the goal of improving therapeutic Inc. on up to three early-stage innovative antibody drug options for patients with acute lymphoblastic leukemia conjugate programs and with Nippon Shinyaku Co., Ltd. (ALL), we continue to make progress in identifying a to develop and market Defitelio and Vyxeos in Japan. new, improved and potentially long-acting crisantaspase product candidate. 2017 FINANCIAL HIGHLIGHTS In sleep medicine, we submitted a supplemental NDA for Xyrem earlier this year seeking marketing authorization In 2017 compared to 2016, full-year revenue grew for pediatric narcolepsy patients. For JZP-258, we expect 9% to $1.6 billion, with adjusted earnings per share1 to complete enrollment this year in our Phase 3 study in growth of 9% to $11.04. Investment in R&D grew 11% to narcolepsy patients to support an NDA submission in $162 million on an adjusted non-GAAP basis1 compared 2019, assuming positive safety and efficacy data. We also to 2016 to support our multiple regulatory submissions plan to initiate a Phase 3 study of JZP-258 in idiopathic and expanding R&D pipeline. We ended 2017 well- hypersomnia patients this year. For solriamfetol, we positioned to execute on corporate development continue to enroll patients in our Phase 2 study in opportunities to support our growth strategy, with cash, excessive sleepiness in Parkinson’s disease and expect cash equivalents and investments of $601 million, an to complete enrollment by year end. enhanced debt structure and $1.25 billion available under our revolving credit facility. With our strong cash position, low leverage ratio and anticipated cash generation of over $2.5 billion over the next three years, we are well-positioned to broaden CONTINUING OUR EVOLUTION our portfolio through our internal R&D efforts as well THROUGH STRATEGIC INVESTMENTS as corporate development activities, with a continued focus on long-lived, medically differentiated products With the advancements made in 2017, we are looking and programs aimed at a targeted prescriber base. forward to an eventful 2018. In 2018, we are investing to We expect these investments over time will lead to drive strong performance of our key products, further our sustainable value-creating opportunities that will drive global expansion with multiple regulatory submissions our continued global growth. and plan for several anticipated product launches. Advancing our promising R&D pipeline and bringing In closing, I am very proud of our employees whose additional innovation to our portfolio with ongoing and dedication, integrity and collaboration have brought new programs in our current therapeutic areas continue life-changing therapeutic options to patients. We are to be a priority in 2018. deeply honored to serve the unmet needs of our patients and their families around the world in fulfilling our mission In hematology/oncology, we are focused on positioning of improving patients’ lives and delivering meaningful Vyxeos as the new backbone of AML therapy, with and innovative products in the areas of sleep and multiple planned studies intended to evaluate Vyxeos hematology/oncology. both alone and in combination with targeted therapies in a variety of AML patient populations. For Defitelio, we Sincerely, are developing treatment options for rare, life-threatening conditions related to endothelial cell damage following stem cell transplant, including the prevention of hepatic veno-occlusive disease (VOD), prevention of acute graft- versus-host disease (aGvHD) and the treatment Bruce C. Cozadd of transplant-associated thrombotic microangiopathy Chairman and Chief Executive Officer Expanding R&D Pipeline PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY Oxybate IMGN779 Solriamfetol for ES in JZP-258 Solriamfetol for ES in Once-Nightly Dosing for R/R Parkinson's Disease for Narcolepsy OSA and Narcolepsy CD33+ AML Complete enrollment Complete enrollment PDUFA date Dec 20, by YE18 by 4Q18 2018; EU submission expected late 2018 Asparaginase IMGN632 for Defibrotide JZP-258 for Xyrem for for ALL/other hematological for prevention Idiopathic Pediatric Narcolepsy hematological malignancies of aGvHD Hypersomnia sNDA submitted 2Q18 malignancies First patient in 1Q18 Phase 3 study initiation planned 2H18 CombiPlex Defibrotide Defibrotide for Vyxeos for Pre-clinical evaluation for TA-TMA prevention of VOD High-Risk AML of oncology therapeutic Pivotal Phase 2 study site First patient in 1Q17 Potential EU approval combinations activation planned 4Q18 expected as early as summer 2018 Recombinant Vyxeos for pegaspargase Myelodysplastic for hematological Syndrome Sleep malignancies Phase 2 study initiation Hematology/Oncology planned 2H18 (co-op group) Opt-in Opportunity Financial Performance Total Revenues Net Income per Diluted Share (in millions) $1,800 $12.00 GAAP Non-GAAP Adjusted (unaudited)1 1,619 $110 $1488 $10.1 $9.45 $1,200 $12 $8.00 $796 $6.41 $52 $600 $4.00 $0 $0.00 2015 2016 2017 2015 2016 2017 1 Reconciliations of GAAP reported net income (and related per share amounts) to non-GAAP adjusted net income (and related per share amounts) for 2015, 2016 and 2017 and reconciliations of GAAP R&D expense to non-GAAP adjusted R&D expense for 2016 and 2017 can be found on page 54 of the enclosed Proxy Statement. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY Registered in Ireland – No. 399192 Fifth Floor, Waterloo Exchange Waterloo Road Dublin 4, Ireland NOTICE OF 2018 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 2, 2018 Proxy Dear Shareholder: You are cordially invited to attend the 2018 annual general meeting of shareholders (the “annual meeting”) of Jazz Pharmaceuticals plc, a public limited company formed under the laws of Ireland (the “company”). The annual meeting will be held on Thursday, August 2, 2018, at 10:30
Recommended publications
  • Alkermes Public Limited Company

    Alkermes Public Limited Company

    ALKERMES PUBLIC LIMITED COMPANY Directors’ Report and Consolidated Financial Statements For the Year Ended March 31, 2013 ALKERMES PLC Table of Contents Page Directors’ Report .......................................................... 2 Statement of Directors’ Responsibilities .......................................... 56 Independent Auditors’ Report—Group ........................................... 57 Consolidated Profit and Loss Account ........................................... 59 Consolidated Statement of Comprehensive Income (Loss) ............................. 60 Consolidated Balance Sheet ................................................... 61 Consolidated Statement of Cash Flows ........................................... 63 Consolidated Reconciliation of Shareholders’ Funds ................................. 62 Notes to the Consolidated Financial Statements .................................... 64 Independent Auditors’ Report—Company ......................................... 111 Company Balance Sheet ..................................................... 113 Notes to the Company Financial Statements ....................................... 114 1 DIRECTORS’ REPORT For the Year Ended March 31, 2013 The directors present their report and audited consolidated financial statements for the fiscal year ended March 31, 2013. The directors have elected to prepare the consolidated financial statements in accordance with section 1 of the Companies (Miscellaneous Provisions) Act, 2009, which provides that a true and fair view of the state of
  • In Re: Alkermes Securities Litigation 03-CV-12091-Consolidated

    In Re: Alkermes Securities Litigation 03-CV-12091-Consolidated

    Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 1 of 49 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS In re ALKERMES SECURITIES ) Master Docket No. 03-CV-12091-RCL LITIGATION ) ) CLASS ACTION This Document Relates To: ) ) ALL ACTIONS. ) ) ) CONSOLIDATED COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS Case 1:03-cv-12091-RCL Document 39 Filed 07/12/2004 Page 2 of 49 SUMMARY AND OVERVIEW 1. This is a securities class action on behalf of all purchasers of the common stock of Alkermes, Inc. (“Alkermes” or the “Company”) between April 22, 1999 and July 1, 2002 (the “Class Period”), against Alkermes and certain of its officers and directors for violations of the Securities Exchange Act of 1934 (the “Exchange Act”). 2. Alkermes is a biopharmaceutical company focused on the development of controlled- release drug delivery technologies and their application to existing or new drug therapies. Among the drug delivery technologies defendants seek to develop are sustained-release systems based on biodegradable polymeric microspheres, including those based on Medisorb polymers. 3. In 1996, Alkermes entered into an agreement with JPI Pharmaceutical International (“Janssen”), an affiliate of pharmaceutical giant Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (“Johnson & Johnson”), to develop an injectable form of the schizophrenic drug Risperdal, based upon the Medisorb polymer technology, called Risperdal Consta. Janssen has marketed the oral form of Risperdal since 1993, with sales of $2.3 billion in 2003. According to a December 12, 2001 report by analysts Thomas Weisel Partners, LLC (“Thomas Weisel”), during the Class Period, oral Risperdal was the most prescribed drug in the $5.3 billion atypical antipsychotic market.
  • Explanation of Conflict of Interest Disclosure Parts: Part One: All

    Explanation of Conflict of Interest Disclosure Parts: Part One: All

    Explanation of Conflict of Interest Disclosure Parts: Part One: All Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical companies doing business with or proposing to do business with ACNP over past 2 years (Jan. 2011-Present) Part Two: Income Sources & Equity of $10,000 or greater Part Three: Financial Involvement with a pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products or companies doing business with or proposing to do business with ACNP which constitutes more than 5% of personal income (Jan. 2011-Present): Part Four: Grants from pharmaceutical or biotechnology company, a company providing clinical assessment, scientific, or medical products directly, or indirectly through a foundation, university, or any other organization (Jan. 2011-Present) Part Five: My primary employer is a pharmaceutical/biotech/medical device company. 2012 Program Committee Disclosures Anissa Abi-Dargham: Part 1: Pfizer; Otsuka; Takeda; Sunovion; Shire; Roche; Pierre Favre; Part 2: Pierre Favre William Carlezon: Part 1: Referring to 2010-2011: Scientific Advisory Board, Myneurolab.com; Consultant, Concert Pharmaceuticals; Consultant, Lantheus Medical Imaging; Consultant, Transcept Pharmaceuticals, (Spouse) Senior Scientist, EMD Serono; Part 2: (Spouse) Senior Scientist, EMD Serono, Part 3: (Spouse) Senior Scientist, EMD Serono Cameron Carter: Part1: GlaxoSmithKline research; Part 4: GlaxoSmithKline Karl Deisseroth: Part
  • 2012 Financial Markets Preview Living Creatively

    2012 Financial Markets Preview Living Creatively

    REPRINT FROM JANUARY 2, 2012 BioCentury ™ THE BERNSTEIN REPORT ON BIOBUSINESS Article Reprint • Page 1 of 8 2012 Financial Markets Preview Living creatively By Stacy Lawrence “As the capital markets Viren Mehta of Mehta Partners. “Many Senior Writer companies don’t have any option but to For small, early stage biotech compa- continue to be difficult, raise at lower valuations.” nies, 2012 could be the year of living traditional investors are able He added: “Many companies are not creatively. able to defer any longer. The moment Although public biotechs raised more to extract terms that are comes for many companies when they funds last year than ever before, the vast have to swallow hard and accept painful majority of the money was debt financing more and more onerous.” dilution.” by established companies with marketed products. Thus while the overall numbers Todd Wyche, Brinson Patrick look good and are likely to continue to do Cash on hand so, precommercial companies will have to large and mid-cap companies (see “The Market volatility and macroeconomic get creative with their financings. 1% Effect,” page 2). risk had most buysiders sitting on the Many of these companies avoided rais- In 2011, public biotechs raised $43 sidelines through the back half of 2011. ing money in 2011 because they didn’t billion, easily eclipsing the record $33.1 Bankers are hopeful that this year will be like the valuations, but Wall Streeters say billion in 2000. But debt accounted for more stable, in which case investors might they are now running out of cash. As a 82% of the total dollars raised, compared be willing to support more deal flow dur- result, they will have to use the tricks at to only 19% in 2000 (see “Debt Domi- ing 1H12 (see “Fear Factor,” page 5).
  • Amgen Inc. V. Sanofi, No

    Amgen Inc. V. Sanofi, No

    No. IN THE Supreme Court of the United States ———— AMGEN INC., AMGEN MANUFACTURING LIMITED, AND AMGEN USA, INC., Petitioners, v. SANOFI, AVENTISUB LLC, REGENERON PHARMACEUTICALS INC., AND SANOFI-AVENTIS U.S., LLC, Respondents. ———— On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit ———— PETITION FOR A WRIT OF CERTIORARI ———— STUART L. WATT JEFFREY A. LAMKEN WENDY A. WHITEFORD Counsel of Record ERICA S. OLSON MICHAEL G. PATTILLO, JR. EMILY C. JOHNSON SARAH J. NEWMAN AMGEN INC. MOLOLAMKEN LLP One Amgen Center Drive The Watergate, Suite 660 Thousand Oaks, CA 91320 600 New Hampshire Ave., NW (805) 447-1000 Washington, D.C. 20037 (202) 556-2000 [email protected] Counsel for Petitioners :,/621(3(635,17,1*&2,1&± ±:$6+,1*721'& QUESTION PRESENTED The 1952 Patent Act requires patents to “contain a written description of the invention, and of the manner and process of making and using it.” 35 U.S.C. §112(a). The “written description” must be “in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same.” Ibid. “The object of the statute is to require the patentee to describe his invention so that others may construct and use it after the expiration of the patent.” Schriber-Schroth Co. v. Cleveland Tr. Co., 305 U.S. 47, 57 (1938). The Federal Circuit has construed §112(a) as impos- ing separate “written description” and “enablement” re- quirements subject to different standards.
  • Corporate Responsibility Report

    Corporate Responsibility Report

    Corporate Responsibility Report October 2019 ©2019 Alkermes. All rights reserved. Table of Contents Section 1: Introduction . 2 Section 2: About Our Company . 3 Section 3: Our Approach to Corporate Responsibility . 4 Section 4: Environment . 6 Section 5: Social . 15 Section 6: Governance . 23 Section 7: The Future of Corporate Responsibility at Alkermes and About This Report . 27 ALKERMES • CORPORATE RESPONSIBILITY REPORT 1 SECTION 1 INTRODUCTION A Message from Our CEO Alkermes was founded by pioneers in the field of Inspired by the courage and determination of individuals neuroscience, and their legacy of innovation and in these frequently underserved and marginalized scientific excellence — applied to the real-world needs communities, we are driven to develop medicines and of patients — remains central to our mission. Alkermes contribute to systemic solutions that we hope will have technologies and discoveries have contributed to a meaningful impact on the lives of patients. important medicines that continue to shape the treatment landscape in many disease areas. Today, Our Commitment we are distinguished from other biopharmaceutical As we look toward building our business for the companies by our core focus on serious mental illness future, we are guided by the opportunity — and what and addiction — chronic, highly prevalent conditions we believe is our responsibility — to help address the that affect millions of people and represent some of unmet needs of patients and to operate in a sustainable, the most challenging public health issues of our time. socially responsible manner. We firmly believe that doing so is best for our business, our employees, for Great science. Deep compassion.
  • Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01

    Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01

    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 08/08/2015 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 21:25:58 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 10/01/2015 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 65162 AMNEAL PHARMACEUTICALS LLC 00074 ABBOTT LABORATORIES 69238 AMNEAL PHARMACEUTICALS, LLC 68817 ABRAXIS BIOSCIENCE, LLC 53150 AMNEAL-AGILA, LLC 16729 ACCORD HEALTHCARE INCORPORATED 00548 AMPHASTAR PHARMACEUTICALS, INC. 42192 ACELLA PHARMACEUTICALS, LLC 66780 AMYLIN PHARMACEUTICALS, INC. 10144 ACORDA THERAPEUTICS, INC. 55724 ANACOR PHARMACEUTICALS 00472 ACTAVIS 10370 ANCHEN PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 62559 ANIP ACQUISITION COMPANY 45963 ACTAVIS INC. 54436 ANTARES PHARMA, INC. 46987 ACTAVIS KADIAN LLC 52609 APO-PHARMA USA, INC. 49687 ACTAVIS KADIAN LLC 60505 APOTEX CORP. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 63323 APP PHARMACEUTICALS, LLC. 67767 ACTAVIS SOUTH ATLANTIC 42865 APTALIS PHARMA US, INC 66215 ACTELION PHARMACEUTICALS U.S., INC. 58914 APTALIS PHARMA US, INC. 52244 ACTIENT PHARMACEUTICALS 13310 AR SCIENTIFIC, INC. 75989 ACTON PHARMACEUTICALS 08221 ARBOR PHARM IRELAND LIMITED 76431 AEGERION PHARMACEUTICALS, INC. 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 50102 AFAXYS, INC. 24338 ARBOR PHARMACEUTICALS, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 59923 AREVA PHARMACEUTICALS 27241 AJANTA PHARMA LIMITED 76189 ARIAD PHARMACEUTICALS, INC. 17478 AKORN INC 24486 ARISTOS PHARMACEUTICALS, INC. 24090 AKRIMAX PHARMACEUTICALS LLC 67877 ASCEND LABORATORIES, L.L.C. 68220 ALAVEN PHARMACEUTICAL, LLC 76388 ASPEN GLOBAL INC. 00065 ALCON LABORATORIES, INC. 51248 ASTELLAS 00998 ALCON LABORATORIES, INC. 00469 ASTELLAS PHARMA US, INC. 25682 ALEXION PHARMACEUTICALS 00186 ASTRAZENECA LP 68611 ALIMERA SCIENCES, INC.
  • ENDO INTERNATIONAL PLC (Exact Name of Registrant As Specified in Its Charter)

    ENDO INTERNATIONAL PLC (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): January 16, 2015 ENDO INTERNATIONAL PLC (Exact name of registrant as specified in its charter) Ireland 001-36326 Not Applicable (State or other jurisdiction of (Commission (I.R.S Employer incorporation or organization) File Number) Identification No.) Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland Not Applicable (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code 011-353-1-268-2000 Not Applicable Former name or former address, if changed since last report Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01 Other Events. This Current Report on Form 8-K is being filed pursuant to a memorandum of understanding regarding the settlement of certain litigation relating to the proposed merger (the “Merger”) between Auxilium Pharmaceuticals, Inc. (“Auxilium”) and Avalon Merger Sub Inc. (“Merger Sub”) pursuant to that certain Amended and Restated Agreement and Plan of Merger, dated as of November 17, 2014 (the “Merger Agreement”), by and among Auxilium, Endo International plc (“Endo”), Endo U.S.
  • Amgen 2008 Annual Report and Financial Summary Pioneering Science Delivers Vital Medicines

    Amgen 2008 Annual Report and Financial Summary Pioneering Science Delivers Vital Medicines

    Amgen 2008 Annual Report and Financial Summary Pioneering science delivers vital medicines About Amgen Products Amgen discovers, develops, manufactures Aranesp® (darbepoetin alfa) and delivers innovative human therapeutics. ® A biotechnology pioneer since 1980, Amgen Enbrel (etanercept) was one of the fi rst companies to realize ® the new science’s promise by bringing EPOGEN (Epoetin alfa) safe and effective medicines from the lab Neulasta® (pegfi lgrastim) to the manufacturing plant to patients. NEUPOGEN® (Filgrastim) Amgen therapeutics have changed the practice of medicine, helping millions of Nplate® (romiplostim) people around the world in the fi ght against ® cancer, kidney disease, rheumatoid Sensipar (cinacalcet) arthritis and other serious illnesses, and so Vectibix® (panitumumab) far, more than 15 million patients worldwide have been treated with Amgen products. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. 0405 06 07 08 0405 06 07 08 0405 06 07 08 0405 06 07 08 Total revenues “Adjusted” earnings Cash fl ow from “Adjusted” research and ($ in millions) per share (EPS)* operations development (R&D) expenses* (Diluted) ($ in millions) ($ in millions) 2008 $15,003 2008 $4.55 2008 $5,988 2008 $2,910 2007 14,771 2007 4.29 2007 5,401 2007 3,064 2006 14,268 2006 3.90 2006 5,389 2006 3,191 2005 12,430 2005 3.20 2005 4,911 2005 2,302 2004 10,550 2004 2.40 2004 3,697 2004 1,996 * “ Adjusted” EPS and “adjusted” R&D expenses are non-GAAP fi nancial measures. See page 8 for reconciliations of these non-GAAP fi nancial measures to U.S.
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry

    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry

    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Form

    UNITED STATES SECURITIES and EXCHANGE COMMISSION Form

    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☒ 1934 For the fiscal year ended December 31, 2008 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☐ OF 1934 Commission file number 000-12477 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One Amgen Center Drive, 91320-1799 Thousand Oaks, California (Zip Code) (Address of principal executive offices) (805) 447-1000 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(g) of the Act: Common stock, $0.0001 par value; preferred share purchase rights (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
  • US Pharma's Business Model

    US Pharma's Business Model

    INNOVATION-FUELLED, SUSTAINABLE, INCLUSIVE GROWTH Working Paper US Pharma’s Business Model: Why It Is Broken, and How It Can Be Fixed William Lazonick Matt Hopkins Ken Jacobson Mustafa Erdem Sakinç Öner Tulum The Academic-Industry Research Network 13/2017 May This project has received funding from the European Union Horizon 2020 Research and Innovation action under grant agreement No 649186 US Pharma’s Business Model: Why It Is Broken, and How It Can Be Fixed William Lazonick Matt Hopkins Ken Jacobson Mustafa Erdem Sakinç Öner Tulum The Academic-Industry Research Network (www.theAIRnet.org) Revised, May 22, 2017 Chapter for inclusion in David Tyfield, Rebecca Lave, Samuel Randalls, and Charles Thorpe, eds., The Routledge Handbook of the Political Economy of Science The contents of this chapter are drawn from two contributions by the Academic- Industry Research Network to the United Nations Secretary-General’s High-Level Panel on Access to Medicines: http://www.unsgaccessmeds.org/list-of-contribution/ William Lazonick is Professor of Economics, University of Massachusetts Lowell; Visiting Professor, University of Ljubljana; Professeur Associé, Institut Mines- Télécom; and President, The Academic-Industry Research Network (theAIRnet); Matt Hopkins, Ken Jacobson, Mustafa Erdem Sakinç, and Öner Tulum are researchers at theAIRnet. Jacobson is also theAIRnet communications director. Sakinç has just completed a PhD in economics at the University of Bordeaux. Tulum is a PhD student at the University of Ljubljana. Funding for this research came from the Institute for New Economic Thinking (Collective and Cumulative Careers project), the European Union Horizon 2020 Research and Innovation Programme under grant agreement No.